Shanghai Henlius Biotech Inc (HKSE:02696) Stock Price, Trades & News

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.22
Equity-to-Asset	0.32
Debt-to-Equity	0.91
Debt-to-EBITDA	2.69
Interest Coverage	9.05
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.76	Distress Grey Safe
Beneish M-Score	-1.78	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	26.8
	3-Year Book Growth Rate	33.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	4.05
	Future 3-5Y Total Revenue Growth Rate Estimate	6.98

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	61.37
	9-Day RSI	62.55
	14-Day RSI	59
	3-1 Month Momentum %	-10.91
	6-1 Month Momentum %	-14.71
	12-1 Month Momentum %	-24.34

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.71
	Quick Ratio	0.58
	Cash Ratio	0.16
	Days Inventory	155.81
	Days Sales Outstanding	69.96
	Days Payable	167.14

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	0.37

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	74.76
	Operating Margin %	13.9
	Net Margin %	12.4
	EBITDA Margin %	20.14
	FCF Margin %	1.57
	OCF Margin %	19.55
	ROE %	24.1
	ROA %	7.25
	ROIC %	8.07
	3-Year ROIIC %	66.37
	ROC (Joel Greenblatt) %	34.2
	ROCE %	13.95
	Years of Profitability over Past 10-Year	3

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	40.54
	Forward PE Ratio	35.95
	PE Ratio without NRI	40.54
	Price-to-Owner-Earnings	64.1
	PS Ratio	5.01
	PB Ratio	8.36
	Price-to-Free-Cash-Flow	315.96
	Price-to-Operating-Cash-Flow	25.62
	EV-to-EBIT	39.79
	EV-to-Forward-EBIT	34.76
	EV-to-EBITDA	27.08
	EV-to-Forward-EBITDA	22.74
	EV-to-Revenue	5.45
	EV-to-Forward-Revenue	4.12
	EV-to-FCF	347.03
	Price-to-GF-Value	2.18
	Earnings Yield (Greenblatt) %	2.51
	FCF Yield %	0.31

GF Value™: HK$30.91

HKSE:02696

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with 02696. Try a 7-Day Free Trial to check it out.

Shanghai Henlius Biotech Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Shanghai Henlius Biotech Inc Stock Events

Financials Calendars

	Event	Date	Price (HK$)
No Event Data

Press Release

	Subject	Date
	Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved	2024-03-21
	Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development	2024-03-04
	HANSIZHUANG Sets Sail in Indonesia Market	2023-12-28
	The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA	2023-12-12
	Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth	2023-08-25
	Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023	2023-06-28
	Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues	2023-03-31
	EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)	2023-03-23
	Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02	2023-02-15
	First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US	2022-11-29

10/Page

Articles on Shanghai Henlius Biotech Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Shanghai Henlius Biotech Inc - Class H

Business Description